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the patient's leukemia type, most likely mediated by trogocytosis
(Somanchi et al., 2012), suggesting recent interaction with the leuke-
mia cells and possible anti-leukemic activity. It is important to note
that although the patients have this activated andmature NK cell subset
that appears to interact with their leukemia, these NK cells are not
sufﬁcient for clearing the cancer. It is not clear whether this is a result
of non-cytotoxic interactions, resistance mechanisms, or inadequate
effector numbers. If larger numbers of these NK cell subsets are needed,NK cells possess tremendous diversity with respect to receptor
repertoire, with the average person having between 6000 and 30,000
different phenotypes (Horowitz et al., 2013). With variegated expres-
sion of over 30 activating and inhibitory receptors, identifying which
among these many phenotypes is responsible for recognition and elim-
ination of speciﬁc viral infections or malignancies has not been feasible
in most circumstances. In this issue of EBioMedicine, Krzywinska et al.
(Krzywinska et al., 2015) have identiﬁed CD45RO as a unique marker
of activated natural killer (NK) cells. CD45 is a phosphatase associated
with lymphocyte signaling (Tonks et al., 1988; Ledbetter et al., 1988;
Charbonneau et al., 1988) which is expressed in several forms that can
be discriminated by antibodies to extracellular determinants. The splice
variant CD45RO is the short isoform of CD45, which is expressed on
memory T cells (Sanders et al., 1988; Thomas and Lefrancois, 1988).
An NK cell population expressing both CD45RA and CD45RO was
identiﬁed in patients with hematological malignancies, and these cells
possessed features of having recently been activated. By further demon-
strating evidence of recent interaction with leukemic cells in vivo, the
authors suggest that CD45RO identiﬁes a subpopulation of NK cells
with anti-leukemic activity. If CD45RO proves to be a reliable in vivo
marker of activated NK cells, it could be of potential use in identifying
or selecting NK cells with context-speciﬁc activity (e.g., anti-tumor,
anti-viral, auto-immune, decidual).
The novel CD45ROpos NK cell subset is identiﬁed as mature by being
CD56dim and having co-expression of CD16, killer cell immunoglobulin-
like receptors (KIR), and theNKmaturationmarker, CD57. The CD45RO-
pos NK cells are large in size with increased granularity, indicative of an
activated or primed state. Interestingly, these cells have decreased gran-
zyme B content when compared to the CD45RAposROneg expressing NK
cells, suggesting recent degranulation. The authors also show that theom.2015.08.021.
53 Houston, TX, 77030, USA.
. This is an open access article underthis raises the possibility of using CD45RO to identify leukemia-reactive
subsets that can be expanded ex vivo for therapy (Denman et al., 2012)
without a priori knowledge of their receptor repertoire.
Determining the NK cell subsets that are tumor-reactive in cancer
patients remains a challenge. In non-cancer settings in which the target
cells cannot be so easily propagated— or in some cases is unknown— this
may represent an approach for identifying the relevant NK cell subsets
for mechanistic, diagnostic, or therapeutic purposes. Additional work
is needed to determine whether CD45RO is a generalizable marker of
recent NK cell activity or is speciﬁc to leukemic or malignant cell inter-
actions, whether CD45ROpos NK cells are present at diagnosis, how they
are affected by chemotherapy, radiation, and immunotherapy, whether
they represent a cytotoxic, regulatory, or exhausted phenotype, and
whether quantitation of these NK cells during therapy can be used as a
biomarker for survival or response to therapy. Work done in this study
has demonstrated anNK cell subset that has both basic and clinical inter-
est, and further research will determine the importance of this subset in
human disease.
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